Skip to main content
. Author manuscript; available in PMC: 2022 Jul 1.
Published in final edited form as: Dig Liver Dis. 2021 Feb 24;53(7):873–878. doi: 10.1016/j.dld.2021.02.005

Table 2:

Cross-sectional associations between sRAGE, elevated liver enzymes and FIB-4 index by quartiles of sRAGE

Outcome sRAGE Quartile Unadjusted OR (95% CI) p-value Adjusted OR (95% CI) p-value p-for-trend
Elevated ALT Q1 2.19 (1.01–4.75) 0.05 2.82 (1.18–6.76) 0.02 0.03
Q2 1.42 (0.62–3.26) 0.41 1.44 (0.60–3.44) 0.41
Q3 1.53 (0.67–3.47) 0.31 1.59 (0.68–3.72) 0.28
Q4 1 (Reference) 1 (Reference)
Elevated AST Q1 1.00 (0.43–2.35) 1.00 1.16 (0.45–2.99) 0.76 0.33
Q2 1.68 (0.78–3.63) 0.19 1.88 (0.84–4.19) 0.13
Q3 0.72 (0.28–1.82) 0.49 0.78 (0.30–2.00) 0.61
Q4 1 (Reference) 1 (Reference)
Elevated FIB-4 Q1 0.62 (0.43–0.87) <0.01 0.56 (0.37–0.84) <0.01 0.02
Q2 0.83 (0.59–1.17) 0.30 0.86 (0.59–1.24) 0.42
Q3 0.74 (0.52–1.04) 0.08 0.75 (0.52–1.08) 0.12
Q4 1 (Reference) 1 (Reference)

Elevated ALT: >27 in Females, >33 in Males; Elevated AST: >31 in Females, >33 in Males; Elevated FIB-4 Index: ≥1.3

Age (ALT and AST analyses only), Race, Gender, Diabetes (yes/no), BMI (kg/m2), Hypertension (yes/no), Total Cholesterol (mg/dL), HDL (mg/dL), Triglycerides (mg/dL), Tobacco Use (current, former, never), Alcohol Use (current, former, never).